Loading…
Verastem, Inc. is projected to rise to $6.49 by 2027, a +12% move from its current price of $5.80. VSTM is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $5.60 | $5.80 | $6.01 | 0.00% |
| Aug 3 | $5.52 | $5.80 | $6.10 | 0.00% |
| Aug 4 | $5.45 | $5.80 | $6.17 | 0.00% |
| Aug 5 | $5.40 | $5.80 | $6.23 | +0.01% |
| Aug 6 | $5.36 | $5.80 | $6.28 | +0.01% |
| Aug 7 | $5.32 | $5.80 | $6.33 | +0.01% |
| Aug 8 | $5.28 | $5.80 | $6.37 | +0.01% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $5.28 | $5.80 | $6.37 | +0.01% |
| Week 2 | $5.08 | $5.80 | $6.63 | +0.02% |
| Week 3 | $4.93 | $5.80 | $6.83 | +0.03% |
| Week 4 | $4.81 | $5.80 | $7.00 | +0.04% |
| Week 5 | $4.70 | $5.80 | $7.16 | +0.05% |
| Week 6 | $4.61 | $5.80 | $7.31 | +0.06% |
| Week 7 | $4.52 | $5.80 | $7.45 | +0.07% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Verastem, Inc. is a development-stage biopharmaceutical company focused on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.
The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc.
to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS, which in Phase 1/2 trial entitled RAMP 203; VS-7375, and VS-7375-101 is a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers; and AVMAPKI, FAKZYNJA, CO-PACK, is an avutometinib capsules, and defactinib tablets.
The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.
Verastem, Inc. (VSTM) is a cancer-focused biopharmaceutical company with a portfolio centered on Avutometinib and Defactinib, two oral small molecule therapies. The stock trades with a current price of $6.03 and a market capitalization of $529.88M, ranking it at 2891 by market position.
The near-term price signal presents a cautious start, while the longer horizon shows an expanding set of upside targets as shown in the year-by-year forecast. The outlook includes multiple years with neutral to bullish sentiment and progressively higher average prices through 2050.
A major floor 59.0% below — a decisive break under it would weaken the trend.
The nearest floor, 40.5% below — buyers have tended to step in here.
The nearest ceiling, 7.4% above — a clean break opens room to run.
A major ceiling 36.9% above — clearing it would confirm fresh momentum.
Key VSTM support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of VSTM market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $6.04 | Sell | $5.98 | Sell |
| MA 10 | $6.01 | Sell | $5.93 | Sell |
| MA 20 | $5.69 | Buy | $5.63 | Buy |
| MA 50 | $4.69 | Buy | $5.19 | Buy |
| MA 100 | $5.11 | Buy | $5.35 | Buy |
| MA 200 | $6.44 | Sell | $5.87 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 57.37 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | 19.64 | Neutral |
| Williams %R (14) | -65.15 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | 1.22 | Buy |
| Bollinger %B (20,2) | 0.56 | Neutral |
| Stochastic %K (14) | 34.85 | Neutral |
| TRIX (15) | 1.37 | Buy |
| Awesome (5,34) | 1.04 | Buy |
| Ultimate (7,14,28) | 52.29 | Neutral |
| Momentum (10) | -0.23 | Sell |
| Aroon Osc (25) | 88.00 | Buy |
| Hull MA (9) | 6.02 | Sell |
| ADX (14) | 30.91 | Buy |
| ATR (14) | 0.18 | Info |
The 30-day technical picture shows a bullish tilt despite near-term volatility. RSI14 stands at 80, indicating strong momentum. The 50-day simple moving average is $4.45 and the 200-day simple moving average is $6.59, with a key resistance at $6.03 and a support level at $3.45.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.45 | $5.80 | $7.19 | 0% | Neutral | |
| $5.03 | $6.49 | $8.92 | +12% | Neutral | |
| $5.39 | $7.22 | $10.41 | +24% | Bullish | |
| $6.64 | $9.18 | $13.73 | +58% | Bullish | |
| $8.06 | $11.46 | $17.66 | +98% | Bullish | |
| $9.22 | $13.45 | $21.27 | +132% | Bullish | |
| $9.45 | $14.12 | $22.86 | +143% | Bullish | |
| $9.13 | $13.96 | $23.09 | +141% | Bullish | |
| $10.03 | $15.68 | $26.44 | +170% | Bullish | |
| $11.01 | $17.57 | $30.16 | +203% | Bullish | |
| $16.52 | $29.05 | $53.70 | +401% | Bullish | |
| $32.71 | $68.43 | $140.69 | +10.8x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $3.45 | $5.80 | $6.82 | +0.00% |
| September 2026 | $4.70 | $5.61 | $6.92 | -3.24% |
| October 2026 | $4.82 | $5.81 | $7.26 | +3.48% |
| November 2026 | $4.75 | $5.76 | $7.28 | -0.84% |
| December 2026 | $4.61 | $5.63 | $7.19 | -2.31% |
Click any year to see its month-by-month VSTM forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The VSTM price prediction for 2026 points to an average of $5.80 (low $3.45, high $7.19) — a potential gain of 0% on today's $5.80. A consolidation phase looks the most probable path here.
In 2027, VSTM is projected to trade between $5.03 and $8.92, averaging $6.49 — a potential gain of +12% from today's $5.80. That is up +12% on the projected 2026 average. Price action looks broadly range-bound.
Verastem, Inc.'s 2028 outlook centres on $7.22, within a $5.39 to $10.41 range. That is up +11% on the projected 2027 average. That marks a +24% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, VSTM could reach as high as $13.73, with a base case around $9.18 and support toward $6.64 — roughly +58% from $5.80. Momentum favours further upside here.
Expect VSTM to range from $8.06 to $17.66 through 2030. The $11.46 average target implies a +98% move from current prices. That is up +25% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The VSTM price prediction for 2031 points to an average of $13.45 (low $9.22, high $21.27) — a potential gain of +132% on today's $5.80. Momentum favours further upside here.
In 2032, VSTM is projected to trade between $9.45 and $22.86, averaging $14.12 — a potential gain of +143% from today's $5.80. That is up +5% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Verastem, Inc.'s 2033 outlook centres on $13.96, within a $9.13 to $23.09 range. That is -1% versus the projected 2032 average. That marks a +141% change versus current levels. Momentum favours further upside here.
By 2034, VSTM could reach as high as $26.44, with a base case around $15.68 and support toward $10.03 — roughly +170% from $5.80. Buyers look set to stay in control over this stretch.
Expect VSTM to range from $11.01 to $30.16 through 2035. The $17.57 average target implies a +203% move from current prices. That is up +12% on the projected 2034 average. Momentum favours further upside here.
The VSTM price prediction for 2040 points to an average of $29.05 (low $16.52, high $53.70) — a potential gain of +401% on today's $5.80. Buyers look set to stay in control over this stretch.
In 2050, VSTM is projected to trade between $32.71 and $140.69, averaging $68.43 — a potential gain of +10.8x from today's $5.80. That is up +136% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in VSTM today (≈ 172.413793 VSTM) could be worth
$11,798.85
+$10,798.85 (+1080%) by 2050 · US Dollar
Based on the average projected VSTM price of $68.43 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in VSTMwould be worth at today's price.
$1,000 invested in VSTM on Jul 31, 2025 (≈ 162.074552 VSTM) would be worth
$940.03
-$59.97 (-6.0%) today · 0.94× · US Dollar
Based on a VSTM entry price of $6.17 vs. today's $5.8.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $6.05 | $958.68 | -4.1% |
| 1 month ago | $4.1 | $1,414.63 | +41.5% |
| 3 months ago | $5.84 | $993.15 | -0.7% |
| 6 months ago | $6.25 | $928 | -7.2% |
| 1 year ago | $6.17 | $940.03 | -6.0% |
| All time (5.0y) ago | $38.52 | $150.57 | -84.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our VSTM forecast.
Our base-case forecast reaches $12.00 around 2031.
Implied market cap at $12.00: $1.05B
The multi-year forecast points to a rising average price from $6.03 in the near term toward substantially higher levels over time. In 2026 the average is $6.03 with a neutral sentiment and a flat ROI of 0%. The path improves through 2027–2028, where the average rises to $6.54 and $6.59 respectively, with ROI projections of 8.5% and 9.2% and neutral sentiment.
Beginning in 2029, the model turns bullish as the averages climb to $8.54, $10.89, $12.15, and $12.75 across 2029–2032, with increasing ROIs of 41.6%, 80.6%, 101.5%, and 111.4%. The bullish trend persists through 2033–2035 (avg $12.29, $13.15, $14.99) and beyond, with ROIs of 103.9%, 118.1%, and 148.6% respectively. By 2040, the average price is projected at $23.15 with a 284% ROI, and by 2050 the average reaches $55.10 with an 813.8% ROI, supported by a sustained bullish sentiment.
These figures illustrate a clear long-term upside potential, tempered by inherent uncertainty and the usual risks associated with clinical-stage therapeutics. The stated forecasts are estimates, not guarantees.
Tap a question to reveal the answer.
2030 forecast: min $7.39, avg $10.89, max $17.40, ROI 80.6%, sentiment BULLISH.
The forecast shows neutral in 2026–2028 and bullish from 2029 onward, with average prices rising to $10.89 by 2030 and to $55.10 by 2050, and ROIs up to 813.8%. These are estimates, not guarantees.
Yes. The max forecast reaches $21.51 in 2032 and $23.19 in 2034, with higher projections later (2040 max $45.13; 2050 max $120.47). The first year with a max above $20 is 2032.
Market cap is $529.88M and rank is 2891.
Verastem, Inc. Community Discussion
0Share your Verastem, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.